Skip to main
ESTA

ESTA Stock Forecast & Price Target

ESTA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Establishment Labs Hldgs is benefiting from accelerating U.S. Motiva adoption, with August 2026 survey data showing ~23% share as of 2Q26 versus a 12% projection from April 2024, while 58% of surveyed surgeons now actively use Motiva and expect share to rise further. The company’s growth case is reinforced by strong operating momentum, including Q2 revenue of $67.5M (+32% y/y), fourth consecutive quarter of positive adjusted EBITDA at $3.7M, and raised full-year 2026 revenue guidance to $269M-$271M. Its disruptive implant technology, expanding minimally invasive platform, and pipeline opportunities such as Preservé, reconstruction label expansion, and GEM support a longer-term path to stronger revenue growth and free cash flow.

Bears say

Establishment Labs Hldgs is viewed negatively because the company still faces substantial execution and industry risks despite Motiva’s share gains. The excerpts note that Allergan and Mentor are expected to keep ceding share across the forecast horizon, while Tiger Aesthetics remains at only about 2% share and Bimini Health Tech is not expected to gain traction, underscoring a concentrated competitive landscape. Even with above-average revenue growth and attractive gross margin, the business remains exposed to recession risk, competition, funding needs, product-launch failures, tariffs, and intellectual property issues.

ESTA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Establishment Labs Holdings Inc (ESTA) Forecast

Analysts have given ESTA a Strong Buy based on their latest research and market trends.

According to 8 analysts, ESTA has a Strong Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $98.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $98.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Establishment Labs Holdings Inc (ESTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.